PARIS (Reuters) – Sanofi said on Wednesday it expected to file nine regulatory submissions for new drugs over the next 18 months and that its pipeline of new products would support long-term growth.
The French drugmaker, battling to contain the fallout from a safety row in the Philippines over its dengue vaccine, also said it would launch at least 10 pivotal Phase 3 studies in the next year.
The company has been focusing on “multi-targeting” drugs that have the potential to treat more than one disease. One example is dupilumab – developed with U.S partner Regeneron and for which it has already secured approval in eczema in the U.S and Europe – with expected uses in asthma, nasal polyps, eosinophilic esophagitis and food allergies.
“Phase 3 development for dupilumab is now planned in chronic obstructive pulmonary disease (COPD),” Sanofi said in a statement.
Sanofi reiterated its strategy to re-build its position in cancer and said that it expected a first regulatory submission of its monoclonal antibody for relapsed refractory multiple myeloma this year.
Reporting by Matthias Blamont; Editing by Richard Lough